SCHEMBL309818

SCHEMBL309818

Cc1ccc(C(F)(F)F)cc1S(=O)(=O)N1CCN(C(=O)O)[C@@H](CC(C)(C)C)C1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDH1 O75874 1/20 0.41
OPRK1 P41145 2/20 0.41
SMN1; SMN2 Q16637 3/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
ALDH1A1 P00352 1/20 0.39
TSHR P16473 1/20 0.39
ATM Q13315 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
EPHX2 P34913 2/20 0.39
CNR1 P21554 1/20 0.38
CNR2 P34972 1/20 0.38
TRPV4 Q9HBA0 1/20 0.38
KDM4E B2RXH2 1/20 0.38
GAA P10253 2/20 0.38
MAPT P10636 2/20 0.37
GBA1 P04062 1/20 0.37
POLB P06746 1/20 0.37
SMPD1 P17405 1/20 0.37
TDP1 Q9NUW8 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL308314 0.93 EPHX2 (0.46) OPRK1MEN1KMT2AALDH1A1TSHR
SCHEMBL2831496 0.85 IDH1 (0.44) IDH1SMN1; SMN2MEN1KMT2AALDH1A1
SCHEMBL2832484 0.78 EPHX2 (0.48) IDH1MEN1KMT2AALDH1A1TSHR
SCHEMBL309817 0.76 MCL1 (0.43) IDH1MEN1KMT2AALDH1A1TSHR
SCHEMBL2833230 0.74 EPHX2 (0.51) OPRK1MEN1KMT2AALDH1A1TSHR
SCHEMBL2835422 0.72 EPHX2 (0.51) MEN1KMT2AALDH1A1TSHRATM
SCHEMBL309731 0.71 IDH1 (0.49) IDH1MEN1KMT2AALDH1A1TSHR
SCHEMBL12965697 0.71 IDH1 (0.40) IDH1SMN1; SMN2ALDH1A1L3MBTL1KDM4E
SCHEMBL12965420 0.71 CNR2 (0.41) IDH1SMN1; SMN2KMT2AALDH1A1TSHR
SCHEMBL309819 0.71 IDH1 (0.43) IDH1SMN1; SMN2MEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8093249-B2 Pyrazolo[1,5-A]pyrimidine-carbonyl-piperazine derivatives Convergence Pharmaceuticals Limited (GB) 2012-01-10 US disclosed
EP-2313413-A1 PYRAZOLO [1, 5-A] PYRIMIDINE DERIVATIVES Convergence Pharmaceuticals Limited (GB) 2011-04-27 EP disclosed
EP-2300432-A1 PIPERAZINE DERIVATIVES USED AS CAV2.2 CALCIUM CHANNEL MODULATORS Convergence Pharmaceuticals Limited (GB) 2011-03-30 EP disclosed
US-20100016330-A1 Novel Derivatives Convergence Pharmaceuticals Limited (GB) 2010-01-21 US disclosed
WO-2010007074-A1 PYRAZOLO [1, 5-A] PYRIMIDINE DERIVATIVES GLAXO GROUP LIMITED (GB) 2010-01-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100016330-A1 Novel Derivatives CACNB2, CACNA1B, CACNA1D IDH1 2988/4885OPRK1 1030/4885SMN1; SMN2 809/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.